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Dolichol synthesisd carrier embedded in the endoplasmic reticulum (ER) membrane essential for
the synthesis of N-glycans, GPI-anchors and protein C- and O-mannosylation. The availability of dolichol
phosphate on the cytosolic site of the ER is rate-limiting for N-glycosylation. The abundance of dolichol
phosphate is inﬂuenced by its de novo synthesis and the recycling of dolichol phosphate from the luminal
leaﬂet to the cytosolic leaﬂet of the ER. Enzymatic defects affecting the de novo synthesis and the recycling of
dolichol phosphate result in glycosylation defects in yeast or cell culture models, and are expected to cause
glycosylation disorders in humans termed congenital disorders of glycosylation (CDG). Currently only one
disorder affecting the dolichol phosphate metabolism has been described. In CDG-Im, the ﬁnal step of the de
novo synthesis of dolichol phosphate catalyzed by the enzyme dolichol kinase is affected. The defect causes a
severe phenotype with death in early infancy. The present review summarizes the biosynthesis of dolichol-
phosphate and the recycling pathway with respect to possible defects of the dolichol phosphate metabolism
causing glycosylation defects in humans.
© 2009 Elsevier B.V. All rights reserved.1. The de novo synthesis of dolicholDolichol was ﬁrst isolated from animal tissues in 1960 [1]. In 1970 it
was demonstrated that many essential biochemical pathways in
eukaryotic cells relyon a sufﬁcient supplywithdolichol-monophosphate
as a carrier of lipid activated glycans [2,3].
Dolichol is the most prevalent polyisoprenyl glycosyl carrier in
eukaryotes involved in C- [4] and O-mannosylation of proteins, the
formation of glycosylphosphatidylinositol (GPI) anchors [5] and the
N-glycosylation of proteins [6].
The ﬁrst steps of the biosynthetic pathway leading to the
biosynthesis of dolichol are common to the majority of neutral lipids.
Dolichol, ubiquinone and cholesterol are all products of the mevalo-
nate pathway [7].
The ﬁrst step towards the biosynthesis of dolichol, cholesterol and
ubiquinone is the condensation of two molecules of acetyl-CoA. Two
additional carbon atoms descending from acetyl-CoA are added to
the resulting acetoacetyl-CoA generating 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) [8]. Subsequently mevalonate is produced by
reduction via HMG-CoA reductase. Two phosphorylation and one
decarboxylation steps later isopentenylpyrophosphate, an essential
building block for all following products, is generated. The
condensation of three isopentenylpyrophosphates results in farne-lucose; GlcNac, N-acetylgluco-
phatidylinositol; CTP, Cytidine
+49 9394947051.
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ll rights reserved.sylpyrophosphate [9]. All of the above mentioned biosynthetic
reactions are common to the pathways leading to dolichol,
cholesterol and ubiquinone, respectively. This review will concentrate
on deﬁciencies that are solely affecting the biosynthesis of dolichol
and dolichol-phosphate or their recycling, thus affecting reactions
described below.
The ﬁrst step unique to the biosynthesis of dolichol is the
condensation of farnesylpyrophosphate with isopentenylpyropho-
sphate (Fig. 1). This reaction is carried out by speciﬁc cis-
prenyltransferases, which use the product polyprenylpyrophosphate
and additional isopentenylpyrophosphates to successively elongate
the polyprenyl to its ﬁnal length. Cis-isopentenyltransferases appear
to be closely bound to microsomes in mammalian tissues [10]. Later
results suggest that dolichol, at least in part, might be produced in the
peroxisomes [7].
After the ﬁnal isopentenylpyrophosphate has been added to the
growing polyisoprene pyrophosphate chain, both phosphate residues
are released by mono- or pyrophosphatases (Fig. 1). Relevant mono
and pyrophosphatase activities could be demonstrated in microsomal
fractions [11–13].
The α-isoprene unit of the polyprenol is subsequently reduced
by an NADPH dependent microsomal reductase (Fig. 1) [14]. It has
been speculated that the activity of the polyprenol reductase
might be rate-limiting for the synthesis of dolichol [15]. Finally a
dolichol-speciﬁc kinase transfers a phosphate from CTP to dolichol
[16,17].
It could be shown at least in rats that the contribution of dietary
dolichol is negligible for the availability of dolichol in the ER compared
to dolichol descending from de novo synthesis [18]. The newly
Fig. 1. De novo biosynthesis of dolichol-phosphate. Cis-prenyltransferases promote the condensation of farnesylpyrophosphate with several molecules of isopentenylpyrophosphate.
The arising polyprenylpyrophosphate is dephosphorylated and reduced. Dolichol is re-phosphorylated by the dolichol kinase.
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of the ER might then serve as a glycan carrier in the ER membrane.
The chain length of eukaryotic dolichol molecules is species
speciﬁc and differs from 14 to 17 isoprene units in unicellular orga-
nisms like the yeasts Saccharomyces cerevisiae and Schizosaccharo-
myces pombe [19]. Mammalian cells produce longer dolichol mole-
cules with 18–21 isoprene units [20].
Even bacterial cells that prefer undecaprenyl phosphate (also
known as bactoprenol phosphate) which is fully unsaturated, some-
times use dolichol as a glycosyl carrier [21,22].
Due to the overlap between the cholesterol, the farnesyl and
the dolichol pathways, the effect of conditions affecting theavailability and metabolism of cholesterol on the Dol-P pool and
thereby on glycosylation is of special interest. It could be shown
that the availability and metabolism of cholesterol does not directly
correlate with the availability and metabolism of Dol-P [23].
While cholesterol metabolism varied 2200-fold under experimental
conditions, the Dol-P metabolism only varied six-fold. In further
experiments on rat liver slices, Keller et al. did not ﬁnd a
signiﬁcant variation in Dol-P while cholesterol synthesis varied
about 40-fold, indicating that the rate of dolichol phosphate
synthesis in the liver can be maintained on almost the same
level under conditions in which the rate of cholesterol synthesis
varies dramatically [24].
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Fourteen distinct oligosaccharide-pyrophosphoryl dolichol deri-
vates are synthesized during the assembly of the ﬁnal N-glycan
precursor in the ER [6]. During N-glycosylation of proteins, dolichol
phosphate is used by three different enzymes. The GlcNAc-
1-phosphotransferase transfers a GlcNAc-1-P residue descending
from UDP-GlcNAc to Dol-P. The resulting GlcNAc-P-P-Dol is subse-
quently elongated to become Man5GlcNAc2-P-P-Dol. After this
structure has been ﬂipped to the luminal side of the ER, it is
elongated by the action of different enzymes to the complete
precursor oligosaccharide Glc3Man9GlcNAc2-P-P-Dol [6,25].
Incubation of cells with radioactive mannose showed that 1 min
after the addition of the labeled sugar, a signiﬁcant amount of
radioactivity is incorporated in Glc3Man9GlcNAc2-P-P-dolichol and
after 5 min Man9GlcNAc2-P-P-dolichol and larger LLOs start to
accumulate implicating that the process of N-glycan formation on
dolichol can be performed within minutes [26].Fig. 2. Schematic representation of the N-glycosylation, C- and O-mannosylation pathway. (
and inner leaﬂet of the ER. The preassembled oligosaccharide is transferred to the nascent pro
is given under the bar. (B) Proteins will be modiﬁed by GPI-anchors (a) and C- (b) or O-maThis preassembled oligosaccharide structure is transferred to
speciﬁc asparagine residues of the respective protein by a multi-
subunit enzyme complex termed oligosaccharyltransferase [6]
(Fig. 2A). As a consequence, Dol-P-P is released on the luminal leaﬂet
of the ER.
All mannose and glucose residues attached to the Man5GlcNAc2-
P-P-Dol structure inside the ER descend fromMan-P-Dol or Glc-P-Dol,
respectively. Both substrates are generated on the outer ERmembrane
by the action of Dol-P-Mannose synthase (dpm1) [27] and Dol-
P-glucose synthase (Alg5) [28], and subsequently ﬂip on the luminal
leaﬂet of ER membrane by mechanisms that are not yet fully
understood. The biosynthesis of both Man-P-Dol and Glc-P-Dol
requires sufﬁcient amounts of dolichol-phosphate.
Eight molecules of Dol-P are required for the synthesis of one N-
glycan. However, C- and O-mannosylation and GPI anchor biosyn-
thesis also depend on a sufﬁcient supply of Dol-P [4–6].
All three mannose residues that are part of the core structure
common to all GPI-anchors descend from Man-P-Dol (Fig. 2B) whichA) The oligosaccharide precursor structure Glc3Man9GlcNAc2 is assembled on the outer
tein en bloc via oligosaccharyltransferase. The number of required dolichol-P molecules
nnosylation (c) on the inner leaﬂet of the ER.
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Man-P-Dol as a required substrate (Fig. 2B) [4–6].
Dolichol-phosphate is essential for avarietyof different glycosylation
processes implicating glycosylation disorders as a result of defects
affecting the synthesis of Dol-P. Disorders mainly affecting protein
glycosylation are comprised in the rapidly growing group of congenital
disorders of glycosylation (CDG), thus Dol-P synthesis and recycling
defects are suggested to be members of these metabolic disorders [25].
While a relevant decrease in Dol-P causes impaired N-glycosylation,
additionally supplied Dol-P results in increased N-glycosylation,
suggesting that the availability of Dol-P is rate limiting for the N-
glycosylation pathway [29–31].
Moreover, some enzymes involved in the N-glycosylation path-
way are closely regulated by the abundance of certain dolichol
linked glycans. Man-P-dolichol, for example, activates the N-
acetylglucosamine-1-phosphate transferase (GPT-1) that initiates
the synthesis of the precursor N-glycan Glc3Man9GlcNAc2 on dolichol
by allosteric activation [32]. Glc-P-dolichol, on the other hand is a
competitive inhibitor of the activation of GPT-1 by Man-P-dolichol
[32]. Both GlcNAc-P-P-dolichol and GlcNAc-GlcNAc-P-P-dolichol
inhibit the de novo synthesis of GlcNAc-P-P-dolichol by feedback
inhibition [26].
GlcNAc-P-P-dolichol also stimulates Man-P-dolichol synthesis up to
tenfold [33]. Thus N-glycosylation is not only regulated by the
availability of Dol-P but also by the presence of primaryDol-P-P-glycans.
Rosenwald et al. showed that Dol-P accounts for approximately 10% of
total dolichol metabolites, and that the level of Dol-P is constant even
when the activity of enzymes utilizing this substrate is considerably
varied [34]. It is well known that a total disruption of N-glycosylation is
not compatible with life [35]. Therefore, no defects in dolichol
metabolism completely abolishing glycosylation are expected to occur
in humans.
3. Recycling of dolichol phosphate
During the synthesis of one N-glycan, seven Dol-P and one Dol-
P-P with luminally-oriented phosphate residues are released at
the inner ER membrane. Similarly, three molecules of Dol-P are
released during the assembly of one GPI anchor and one is released
during C- and O-mannosylation processes, respectively [36]. In addition
to the de novo synthesis of dolichol phosphate, a high-throughput
recycling pathway for Dol-P exists to supply enough Dol-P sufﬁcient for
the different glycosylation pathways [36]. Due to the compartmentali-
zation of the N-glycan synthesis beginning on the cytosolic side andFig. 3. Recycling of dolichol-phosphate. Recycling of Dol-P and Dol-P-P from the luminal le
glucose from Man-P-Dol and Glc-P-Dol into the lumen of the ER by either mannosyl- or gly
leaﬂet of the ER membrane. (B) The oligosaccharyltransferase transfers the dolichol linke
Subsequently Dolichol-pyrophosphatase (CWH8/DPP1) clears the terminal phosphate ena
ﬂippase. (C) Due to the energetically unfavorable transfer of Dol-P through the ER m
de-phosphorylation of dolichol in the ER by CWH8/DPP1 or another not identiﬁed enzym
re-phosphorylation by another yet unidentiﬁed enzyme distinct from dolichol kinase. Symbending on the luminal side of the ER membrane, a recycling pathway of
Dol-P is necessary (Fig. 3).
An early model of dolichol recycling proposed a complete depho-
sphorylation of Dol-P and Dol-P-P with a subsequent ﬂipping or
diffusion of the freeα saturated polyisoprenol from the luminal to the
cytosolic leaﬂet [36]. Subsequently, dolichol would have to be re-
phosphorylated by a dolichol kinase in order to be reused as glycan
carrier. However, Rush et al. could demonstrate that the known
dolichol kinase (DK1) does not contribute to the recycling pathway of
Dol-P and that CTP is not necessary for the recycling process. This
suggests that Dol-P ﬂips through the ER membrane either by diffusion
or by a ﬂippase and is directly reused for the synthesis of dolichol
linked oligosaccharides (Fig. 3A–B) [37]. Nevertheless, since ﬂipping
of Dol-P is an energetically unfavorable event due to the hydrophilic
head group that has to traverse the hydrophobic ER membrane, it
should be considered that Dol-OH ﬂips through the ERmembrane and
is re-phosphorylated on the cytosolic leaﬂet of the ER by a currently
unknown enzyme with an alternative phosphorylation mechanism
independent of CTP (Fig. 3C). Dol-P-P released by the oligosaccha-
ryltransferase must be converted to Dol-P before translocation to the
cytosolic site of the ER making the action of a pyrophosphatase
converting Dol-P-P to Dol-P an essential feature of the recycling
process [36]. In yeast, a pyrophosphatase (CWH8) with an active site
oriented towards the ER lumen has been characterized catalyzing the
hydrolysis of the beta phosphate fromDol-P-P. As a result of the CWH8
deﬁciency, cells accumulate Dol-P-P [38]. Additionally, a hypoglyco-
sylation phenotype caused by a diminished abundance of the full-
length dolichol linked N-glycan precursor (Glc3Man9GlcNAc2-P-P-
Dol) could be demonstrated [38,39], underlining the conversion of
Dol-P-P to Dol-P as an important step in the recycling of Dol-P. The
mammalian homologue to the CWH8 gene, which has been termed
DolPP1 was cloned and could be shown to correct the phenotype of
CWH8-deﬁcient yeasts [40].
It is still unknown howDol-Pmight ﬂip through the ERmembrane.
In an experimental model, the diffusion rate of Dol-P in vesicles was
far too slow to meet the physiological demand [41] implicating
anothermodel than diffusion for Dol-P ﬂipping. However, no potential
Dol-P-ﬂippase has been characterized to date.
Given that the de novo synthesis of Dol-P is not sufﬁcient to fully
cover the demand of the N-glycosylation pathway, that the deﬁciency
of a pyrophosphatase affecting the conversion of Dol-P-P to Dol-P
causes a deﬁciency of N-glycosylation, that there is a rapid
appearance of Dol-P on the cytoplasmic face of the ER derived from
luminally oriented Dol-P-P, and that no catabolic pathway foraﬂet of the ER membrane to the cytosolic leaﬂet. (A) After the transfer of mannose or
cosyltransferases Dol-P with luminal orientation is released and ﬂips on the cytosolic
d N-glycan to the nascent protein releasing Dol-P-P on the luminal leaﬂet of the ER.
bling Dol-P to ﬂip through the ER-membrane either by diffusion or by a yet unknown
embrane another model of Dol-P-P and Dol-P recycling might be possible with a
e consecutively ﬂipping through the ER membrane and with a subsequent cytosolic
ols are the same as in Fig. 2.
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Dol-P is thus subject to an efﬁcient recycling pathway allowing
multiple rounds of dolichol-linked oligosaccharide synthesis on the
basis of an existing Dol-P pool.
The effects of Dol-P recycling on the availability of Dol-P for N-
glycosylation have yet to be determined. Since CWH8 is not known to
be involved in the de novo synthesis of Dol-P-P and a CWH8 deﬁciency
causes a reduction of dolichol linked oligosaccharides to about 20% in
yeast [39], one must conclude, that a relevant amount of Dol-P
available for N-glycosylation results from recycling of luminally-
oriented Dol-P and Dol-P-P.
4. Enzymes involved in the de novo synthesis and the recycling of
dolichol phosphate
4.1. Cis-prenyltransferases
The cis-prenyltransferases are thought to be the ﬁrst enzymes
committed to the biosynthesis of dolichol alone [42]. They are
considered to catalyze the head-to-tail condensation of farnesyl-
diphosphatewith several isopentenyl diphosphatemolecules togenerate
polyprenyl diphosphate also known as dehydro-dolichol diphosphate.
The mechanism which leads to the length determination of the
polyprenylphosphate has yet to be determined [43]; but two
mechanisms have been suggested. It has been proposed that the
addition of isopentenol-P-P instead of isopentenyl-P-P leads to the
determination of the chain length [44]. Alternatively, Crick et al. [10]
suggest that chain elongation may simply be terminated by the
number of isoprene units themselves. According to the latter
hypothesis, the polyprenyl chain will not be a substrate for cis-
isoprenyltransferase once a speciﬁc length is reached [44].
Cis-prenyltransferases have been cloned and characterized fromboth
prokayotic and eukaryotic organisms such as Micrococcus luteus [45],
Escherichia coli [46], Haemophilus inﬂuenzae [46], Streptococcus pneumo-
niae [46], Arabidopsis thaliana [47] and Saccharomyces cerevisiae [48].
Two proteins with known cis-prenyltransferase activities have
been discovered in yeast, RER2 and SRT1. RER2 mutants exhibit a very
severe growth restriction even at 23 °C. A complete growth inhibition
occurs at 37 °C [49].
N-glycosylation and GPI-anchor biosynthesis are severely affected.
Several ER membrane proteins like Sec12 are mislocalized and
abnormal membrane structures occur within the cells [50].
With SRT1, another cis-prenyltransferase, probably accounting for
the biosynthesis of dolichol in Saccharomyces cerevisiae has been
described. Although SRT1 deﬁcient cells do not show any of the above
mentioned deﬁciencies, cells that are harbouring simultaneous
disruptions of the RER2 and SRT1 gene show a lethal phenotype [50].
Interestingly, spontaneous revertants of RER2 deleted cells (Δrer2)
havebeen found tooverexpress theSRT1geneproduct.Dolicholmolecules
descending from these revertants are approximately ﬁve isoprene units
longer than dolichol of wild type cells. Wild type yeast cells synthesize
dolichol molecules of 14-17 isoprene units whereas SRT1 over expressing
Δrer2 cells produce dolichol with lengths of 19-22 isoprene units [51].
4.2. Polyprenylpyrophosphate phosphatase
The enzyme activity needed to dephosphorylate polyprenyl
pyrophosphate has been demonstrated several times [11,12,52,53].
The described activities would be in accordance with a role of
CWH8 in the de novo synthesis of dolichol-phosphate, where
polyprenyl pyrophosphate has to be converted to polyprenyl before
the reduction of the α-isoprene unit can occur [14]. Since polyprenyl
pyrophosphate is produced by cis-prenyltransferases whose active
sites are exposed to the cytoplasmic surface of the ER [10,54], the
active site of CWH8 has the wrong topology, since it is oriented to the
luminal side of the ER [38].Yet, no mutant or enzyme with polyprenylpyrophosphate phos-
phatase activity and the right topological orientation or impact on
glycosylation could be identiﬁed.
4.3. Dolichol pyrophosphate phosphatase
Previous studies described the capability of crude microsomal
fractions to hydrolyze exogenous Dol-P-P [55–58]. In Saccharomyces
cerevisiae, LPP1 andDPP1 have been shown to dephosphorylate dolichol
pyrophosphate and dolichol phosphate [59,60] in vitro. However, since
no growth or glycosylation deﬁciencies occur in cells deﬁcient in these
enzymes, it is questionable if dolichol phosphates are their primary
substrates in vivo. One enzyme that was shown to convert Dol-P-P to
Dol-P and to a slower rate Dol-P to Dol in yeast was found to be CWH8
[38]. CWH8 is an integral membrane protein with four transmembrane
domains and a luminally oriented active site [38].
As described in the chapter dealing with the recycling of dolichol
phosphate CWH8, deﬁcient cells have a severe hypoglycosylation
phenotype. Although the authors already proposed a pyropho-
sphatase and phosphatase activity and an ER localization of CWH8,
they did not prove the function of the coded protein [39]. In a follow-
up study, a mouse homologue of the CWH8 gene was described
(DOLPP1) [40]. The authors could show a marked preference of the
coded enzyme for Dol-P-P and demonstrate an ER localization of the
protein with its active domain oriented to the ER lumen. Impaired N-
glycosylation in cells deﬁcient in dolichol pyrophosphate phosphatase
is due to a relative lack of Dol-P on the outer leaﬂet of the ER; but
might be additionally inﬂuenced by a product inhibition of the
oligosaccharyltransferase complex by the accumulation of Dol-P-P on
the inner leaﬂet of the ER. The latter aspect is underscored by the
fact that the lack of CWH8mainly affects the N-glycosylation pathway.
O- and C-mannosylation and GPI anchoring do not release Dol-P-P but
Dol-P and are thus unlikely to be inhibited by an accumulation of Dol-
P-P. Accordingly, these pathways are only moderately affected [61].
4.4. Polyprenylreductase
A general hypoglycosylation of proteins has been found in Lec9
Chinese hamster ovary cells (CHO). This cell line shows hypoglyco-
sylation of a variety of proteins. Besides glucuronidase and vesicular
stomatitis virus glycoprotein (G protein), the bulk of [3H]mannose-
labeled proteins revealed an aberrant glycosylation phenotype.
Moreover, the compartmentalization of β-3-hexosaminidase and β-
3-glucuronidase is impaired in Lec9 cells and the function of the
mannose 6-phosphate receptor is altered [62]. This cell line has been
shown to exhibit a dramatic reduction in tumorigenicity if injected in
nude mice [63]. It could be shown that the amount of the fully
glycosylated lipid-linked precursor structure Glc3Man9GlcNAc2-P-P-
Dol was markedly decreased [64]. Lec9 cells incorporate approxi-
mately 40-fold less [3H]-mannose into the fully glycosylated LLO
structure. The incorporation of radioactivity into the minor LLO
intermediate Man5GlcNAc2-P-P-Dol was also decreased, but to a
much lower extent and this truncated structure was more frequently
transferred to protein compared to parental cells. The reduction and
size variation of the lipid-linked oligosaccharides ultimately led to a
ﬁvefold decrease in [3H]-mannose incorporation into protein [64]. It
has been found that Lec9 cells are defective in the synthesis of
dolichol. Lec9 cells synthesize polyprenols of the same chain lengths
as parental cells, but do not efﬁciently reduce the double bond of the
terminal isoprene unit of long-chain prenols. Although cis-α-
unsaturated polyprenol is used as a substrate for oligosaccharide
lipid intermediate biosynthesis, many enzymes have a preference for
the usage of dolichol over its unsaturated polyprenol [62]. It is
noteworthy that Lec9 cells are not totally defective for dolichol
synthesis, as a certain amount of alpha-saturated dolichol could be
detected.
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group share very similar phenotypes. CHB11-1-3 [65], B211 [66]
Lec9.4A [67] and F2A8 [68,69] share the temperature sensitive growth
phenotype and the hypoglycosylation of dolichol and proteins. A
revertant of CHB11-1-3 exhibits a higher speciﬁc cis-prenyltransferase
activity [65]. It has been speculated that CHB11-1-3 is a Km mutant,
since a higher amount of substrate reverses the defect.
Another mutant defective for the reduction of polyprenol to
dolichol has been found in Trypanosoma brucei [70]. The insect form of
the protozoan parasite causing the sleeping sickness in Sub-Saharan
Africa displays mutants that are resistant to ConcanavalinA treatment,
since its major surface glycoprotein procyclin is underglycosylated,
and carries abnormally glycosylated glycostructures. Dolichol linked
oligosaccharides have been shown to be truncated.
Defective ConA 1–1 mutants produce equal amounts of polyprenol
and dolichol, whereas wild type cells almost exclusively produce
dolichol. The relatively high amount of residual dolichol leads to the
conclusion that these cells harbour just one defective allele, or that the
mutated enzyme has a considerable rest activity [70].
Ohkura et al. [71] could show that even in some CDG ﬁbroblasts
that were not further characterized but derived from patients with a
type one isoelectric focusing pattern of serum transferrin, polyprenol
rather than dolichol accumulated. These ﬁndings imply that in these
patients, the lack of dolichol-phosphate might be in part responsible
for the described phenotypes, or that the dolichol synthesis might be
affected by defects in the subsequent metabolism of dolichol linked
oligosaccharides.
So far, no polyprenol reductase gene has been identiﬁed in any
eukaryotic organism. Thus, no mutations leading to the loss of poly-
prenol reductase activity have been detected. Moreover, all putative
mutants producing polyprenols instead of dolichol produced at least a
small amount of the fully saturated dolichol, implicating that null
mutants are lethal.
Mutant cells use the polyprenol compounds to synthesize
glycosylated polyprenols of the same structure; and nearly the same
amount as wild type cells produce the dolichol equivalents. As
Man5GlcNAc2-P-P-Dol accumulates in mutant cells, at least Man-
P-Polyprenol and Glc-P-Polyprenol seem to be utilized at much slower
rates than their dolichol counterparts [68,69].
4.5. Dolichol kinase
Dolichol kinase activity was ﬁrstly described in various cells by
Allen et al. [16]. Dolichol kinase (DK) catalyzes the CTP-dependent
phosphorylation of dolichol and hence the ﬁnal step of the de novo
synthesis of Dol-P [72]. It could be shown that DK activity varies with
the cell cycle and tissue differentiation [29,73,74]. Previously it has
been discussed, that DK also plays a key role in the recycling of Dol-P
[36], but currently it could be shown, that the known enzyme coded
by the DK1 gene is not involved [37]. However, DK activity would be
important to recruit Dol-P from a further pool, the free dolichol pool,
which is located in the ER membrane. The relevance of this pool for a
stable Dol-P level is yet not fully understood.
A gene coding for a dolichol kinase was ﬁrstly identiﬁed in yeast
termed SEC59 [75]. Sec59mutants stopdividingandbecomeenlargedat
the restrictive temperature of 37 °C [75,76]. The cells accumulate and
express incompletely glycosylated secretory proteins at the restrictive
temperature [77]. Additionally O-mannosylation and GPI anchor
synthesis are almost completely blocked [75]. Analysis of dolichol-
linked oligosaccharides in Sec59 deﬁcient yeast showed not only
decreased levels of lipid linked oligosaccharides, but also an altered
LLO pattern with accumulation of Man5-6GlcNAc2-P-P-Dol [76].
Dol-P levels in SEC59 cells are about 50% of wild type yeasts at
the permissive temperature decreasing to less than 10% at the
restrictive temperature. A consecutive increase of Dol was not
observed [75].In 2002, a mammalian DK gene was cloned from a mouse brain
library [40]. At the same time the human DK gene was characterized
[78]. The dolichol kinase is located in the ER with a CTP binding
domain and dolichol kinase activity on the cytoplasmic site of the ER
[79]. Using site-directed mutagenesis it could be shown that deleting
the putative CTP binding site (AA459-474) or a mutation of selected
conserved residues within the cytoplasmic loop signiﬁcantly impairs
or abolishes dolichol kinase activity [79]. Dolichol kinase is a key
regulator of the Dol-P synthesis and therefore indirectly regulates the
rate of protein glycosylation [80–82].
5. Glycosylation disorders in humans caused by dolichol
phosphate synthesis or recycling defects
Currently only one disorder affecting the biosynthetic pathway or
recycling of dolichol phosphate has been described.
5.1. Dolichol kinase deﬁciency
A deﬁciency of dolichol kinase, catalyzing the ﬁnal step of dolichol
phosphate synthesis was the ﬁrst defect of the Dol-P pathway known
to cause a severe hypoglycosylation phenotype in humans. We could
describe four patients from two unrelated families suffering from a
dolichol kinase defect named CDG-Im. IEF of serum transferrin
showed a severe hypoglycosylation. A decrease in the activity of
glycosylated clotting factor, typical for CDG I, was present. All patients
died within the ﬁrst year of life [83].
Both pairs of siblings were of consanguineous ancestry, one of
German, the other of Turkish origin. Length, weight and head
circumference were normal at birth but secondary microcephaly,
developing in the ﬁrst month of life was a common ﬁnding in all
patients. Dry, ichthyosiform or parchmentlike skin was present in
every child and a lack of hair growth or progressive hair loss was
noticed partly involving eyebrows and eyelashes. One child developed
seizures with hypsarrhythmia in the EEG. Muscular hypotonia was
common and severe. Two children had progressive dilative cardio-
myopathy, one child suffered from recidivating hypoglycemia. The
children died at a mean age of 6 months.
Two different missense mutations (c.295TNA; p.99CysNSer and
c.1322ANC; p.441TyrNSer) were found in the patients' DK1 gene and
dolichol kinase activity in dermal ﬁbroblasts was reduced to fewer than
5%ofhealthycontrols.Mutatedalleleswereunable tocomplementayeast
stain mutant in dolichol kinase. Since Dol-P is of special importance for
the transport ofMan andGlc into the ER, onewould expect thatﬁbroblast
of CDG-Im show truncated dolichol-linked oligosaccharides between the
assembly of Man5GlcNAc2-P-P-Dol and Glc3Man5GlcNac2-P-P-Dol. How-
ever, labeling of patients' ﬁbroblasts showed no signiﬁcant alteration in
the dolichol linked oligosaccharide patternwhile the amount of dolichol
linked oligosaccharides was decreased [83].
6. Conclusions and future perspective
Dolichol phosphate is an essential carrier of oligosaccharides
during the synthesis of N-glycans, GPI-anchor synthesis and protein
O- and C-mannosylation. Since a total lack of glycosylation is not
compatible with life in yeast and mammals, biochemical defects
completely disabling Dol-P synthesis are not to be expected in
humans. Generally defects affecting the de novo synthesis have to be
differentiated from defects affecting the recycling of Dol-P.
Currently only one defect primarily affecting Dol-P synthesis has
been described. A deﬁciency of dolichol kinase, the latest step of the
de novo synthesis of Dol-P causes a severe disorder belonging to the
group of congenital disorders of glycosylation with death of all four
described patients within the ﬁrst year of life. The de novo synthesis of
Dol-P shares several metabolic steps with other important metabolic
pathways including cholesterol, ubiquinone, geranyl and farnesyl
894 J. Denecke, C. Kranz / Biochimica et Biophysica Acta 1792 (2009) 888–895synthesis. Thus early defects are expected to cause severe phenotypes
or embryonic lethality.
It can be assumed, that in the future, further defects affecting the
de novo synthesis and the recycling of Dol-P will be detected revealing
more clues about the complex impact on glycosylation andmembrane
organization due to a lack of dolichol phosphate.
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